WAVE Life Sciences (FRA:1U5) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1U5 WAVE Life Sciences Ltd FRA:1U5
59 GF Score
Price €5.00
GF Value €3.66
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is WAVE Life Sciences LT-Debt-to-Total-Asset?

WAVE Life Sciences FRA:1U5 -3.85% 59 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates FRA:1U5 with a GF Score™ of 59/100 and a GF Value™ of €3.66 (Significantly Overvalued). The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. WAVE Life Sciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

WAVE Life Sciences's long-term debt to total assets ratio declined from Mar. 2025 (0.05) to Mar. 2026 (0.01). It may suggest that WAVE Life Sciences is progressively becoming less dependent on debt to grow their business.

WAVE Life Sciences  (FRA:1U5) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

WAVE Life Sciences LT-Debt-to-Total-Asset Related Terms

WAVE Life Sciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for WAVE Life Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WAVE Life Sciences LT-Debt-to-Total-Asset Chart

WAVE Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.22 0.09 0.05 0.02

WAVE Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.05 0.02 0.01
FRA:1U5
59GF Score
WAVE Life Sciences Ltd FRA:1U5
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WAVE Life Sciences LT-Debt-to-Total-Asset Calculation

WAVE Life Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=8.032/545.278
=0.01

WAVE Life Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=6.39/504.766
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
WAVE Life Sciences (FRA:1U5) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on WAVE Life Sciences and its competitors.
Is WAVE Life Sciences' LT-Debt-to-Total-Asset too high?
WAVE Life Sciences' current LT-Debt-to-Total-Asset is 0.01. Overall, WAVE Life Sciences has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WAVE Life Sciences' LT-Debt-to-Total-Asset compare to CGEM and LXRX?
WAVE Life Sciences' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on WAVE Life Sciences and its competitors. WAVE Life Sciences's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WAVE Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, WAVE Life Sciences (FRA:1U5) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.66, compared to a current price of €5.00 — trading 36.6% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. WAVE Life Sciences' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For WAVE Life Sciences (FRA:1U5), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WAVE Life Sciences (FRA:1U5) Overvalued in 2026?

Based on GuruFocus' analysis, WAVE Life Sciences stock appears to be overvalued. The current stock price of €5.00 is trading 36.6% above its estimated GF Value™ of €3.66. GuruFocus considers WAVE Life Sciences to be Significantly Overvalued.

Key valuation signals for FRA:1U5:

  • LT-Debt-to-Total-Asset: 0.01
  • GF Value™: €3.66 vs. price of €5.00 (36.6% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the FRA:1U5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WAVE Life Sciences Business Description

Other Exchanges WVE:USA1U5:Germany
Address 7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
59GF Score

Get the complete analysis for FRA:1U5

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.00
Price
€3.66
GF Value